PATIENTS’ PREFERENCES IN CHOOSING THERAPY FOR RETINAL VEIN OCCLUSIONS

Purpose: The purpose of this study was to assess preference values for vein occlusions with macular edema and to determine how this may affect patient perceptions of potential treatments. Methods: The Submacular Surgery Trials Vision Preference Value Scale and questions regarding enthusiasm for potential treatments were administered to 153 patients with vein occlusion. Univariate analyses identified predictors of preference values, followed by adjustment for potential confounders using multivariate linear regression. Relationships between preference values and enthusiasm for potential treatments were assessed. Results: The mean preference values ± SD were similar for patients with branch vein occlusions and central vein occlusions (0.65 ± 0.20). Lower preference values were associated with duration of occlusion of >2 years (P = 0.03) and poorer last-recorded visual acuity (P = 0.02). Approximately one half of patients were moderately or very enthusiastic about undergoing intravitreal injection. Sixty-nine percent of branch vein occlusion patients were moderately or very enthusiastic about the standard of care, laser photocoagulation; only one third of central vein occlusion patients were moderately or very enthusiastic about standard observation. Conclusions: These data suggest that vein occlusion with macular edema has a significant impact on quality of life. Most patients were willing to undergo potentially invasive treatment.

[1]  A. Lindblad,et al.  Responsiveness of the National Eye Institute Visual Function Questionnaire to progression to advanced age-related macular degeneration, vision loss, and lens opacity: AREDS Report no. 14. , 2005, Archives of ophthalmology.

[2]  T. Williamson,et al.  Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion. , 2005, American journal of ophthalmology.

[3]  H. Flynn,et al.  Intravitreal triamcinolone acetonide for macular edema associated with diabetic retinopathy and venous occlusive disease: it's time for clinical trials. , 2005, Archives of ophthalmology.

[4]  S. Sacu,et al.  Intravitreal triamcinolone acetonide in patients with macular oedema due to central retinal vein occlusion. , 2005, Acta ophthalmologica Scandinavica.

[5]  C. Evereklioglu,et al.  The Efficacy of Intravitreal Triamcinolone Acetonide on Macular Edema in Branch Retinal Vein Occlusion , 2005, European journal of ophthalmology.

[6]  Harris A. Jaffee,et al.  Patients' perceptions of the value of current vision: assessment of preference values among patients with subfoveal choroidal neovascularization--The Submacular Surgery Trials Vision Preference Value Scale: SST Report No. 6. , 2004, Archives of ophthalmology.

[7]  E. Bass,et al.  Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality-of-life findings: SST report no. 12. , 2004, Ophthalmology.

[8]  R. Haddad,et al.  Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. , 2004, Archives of ophthalmology.

[9]  C. Puliafito,et al.  Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. , 2004, Archives of ophthalmology.

[10]  E. Bass,et al.  Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4. , 2004, American journal of ophthalmology.

[11]  M. Maguire.  Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). , 2004, Ophthalmology.

[12]  N. Bressler,et al.  Relative contributions of reduced vision and general health to NEI-VFQ scores in patients with neovascular age-related macular degeneration. , 2004, Archives of ophthalmology.

[13]  N. Bressler,et al.  Is adjustment of National Eye Institute Visual Function Questionnaire scores for general health necessary in randomized trials? , 2004, American journal of ophthalmology.

[14]  H. Ozdemir,et al.  Intravitreal triamcinolone acetonide for the treatment of central retinal vein occlusion in young patients. , 2004, Retina.

[15]  J. Holladay,et al.  Visual acuity measurements. , 2004, Journal of cataract and refractive surgery.

[16]  P. Radice,et al.  Optical coherence tomography evaluation of macular edema after radial optic neurotomy in patients affected by central retinal vein occlusion , 2004, Seminars in ophthalmology.

[17]  V. Martinez-Castillo,et al.  Chorioretinal anastomosis after radial optic neurotomy for central retinal vein occlusion. , 2003, Archives of ophthalmology.

[18]  T. Cox,et al.  Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. , 2003, Archives of ophthalmology.

[19]  Gary C. Brown,et al.  Quality of life associated with visual loss: a time tradeoff utility analysis comparison with medical health states. , 2003, Ophthalmology.

[20]  E. Bass,et al.  Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization--SST Report No. 1. , 2003, Archives of ophthalmology.

[21]  S. Bressler,et al.  National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10. , 2003, Archives of ophthalmology.

[22]  M. Ip,et al.  Intravitreous triamcinolone acetonide as treatment for macular edema from central retinal vein occlusion. , 2002, Archives of ophthalmology.

[23]  J. Jonas,et al.  Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion , 2002, Graefe’s Archive for Clinical and Experimental Ophthalmology.

[24]  G. Brown,et al.  Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients , 2002, The British journal of ophthalmology.

[25]  Gary C. Brown,et al.  Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. , 2002, Archives of ophthalmology.

[26]  Tsuguya Fukui,et al.  Utilities Measured by Rating Scale, Time Trade-off, and Standard Gamble: Review and Reference for Health Care Professionals , 2002, Journal of epidemiology.

[27]  Gary C. Brown,et al.  Incremental cost-effectiveness of laser therapy for visual loss secondary to branch retinal vein occlusion , 2002, Ophthalmic epidemiology.

[28]  E. Opremcak,et al.  RADIAL OPTIC NEUROTOMY FOR CENTRAL RETINAL VEIN OCCLUSION: A Retrospective Pilot Study of 11 Consecutive Cases , 2001, Retina.

[29]  R. Hays,et al.  Development of the 25-item National Eye Institute Visual Function Questionnaire. , 2001, Archives of ophthalmology.

[30]  Peter P. Wakker,et al.  The Utility of Health States After Stroke: A Systematic Review of the Literature , 2001, Stroke.

[31]  A. Cruess,et al.  Reliability of the time trade-off technique of utility assessment in patients with retinal disease. , 2001, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[32]  G. Brown,et al.  Quality of life associated with unilateral and bilateral good vision. , 2001, Ophthalmology.

[33]  Gary C. Brown,et al.  Utility values associated with blindness in an adult population , 2001, The British journal of ophthalmology.

[34]  R. Hays,et al.  Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators , 1998 .

[35]  E. Bass,et al.  Preference Values for Visual States in Patients Planning to Undergo Cataract Surgery , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[36]  David J. Wilson,et al.  Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. , 1995, Ophthalmology.

[37]  D. Finkelstein,et al.  Argon laser photocoagulation for macular edema in branch vein occlusion. , 1986, Ophthalmology.

[38]  P. Morse.  Prospective rationale for and results of argon laser treatment of patients with branch retinal-vein occlusion. , 1985, Annals of ophthalmology.

[39]  S D Miller,et al.  Argon laser photocoagulation for macular edema in branch vein occlusion. , 1985, American journal of ophthalmology.

[40]  M. Natarajan,et al.  Central retinal vein occlusion. , 1984, Indian journal of ophthalmology.

[41]  K. Erkiliç,et al.  Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion , 2006, Eye.

[42]  J. Jonas,et al.  Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide , 2005, Eye.

[43]  Gary C. Brown,et al.  A utility analysis correlation with visual acuity: methodologies and vision in the better and poorer eyes , 2004, International Ophthalmology.

[44]  S. Fekrat,et al.  Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. , 2004, American journal of ophthalmology.

[45]  J. Lim,et al.  Intravitreal triamcinolone acetonide for ischaemic macular oedema caused by branch retinal vein occlusion , 2022 .

[46]  G. Beauchamp,et al.  The reproducibility of ophthalmic utility values. , 2001, Transactions of the American Ophthalmological Society.

[47]  Jennifer I. Lim,et al.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. , 2001, Archives of ophthalmology.

[48]  G. Brown,et al.  Utility values and age-related macular degeneration. , 2000, Archives of ophthalmology.

[49]  A. Hillis,et al.  Baseline and early natural history report. The Central Vein Occlusion Study. , 1993, Archives of ophthalmology.

[50]  G. Fish,et al.  Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. Results of a randomized clinical trial. Macular Photocoagulation Study Group. , 1987, Archives of ophthalmology.